PharmTech Drug Digest 11.20
News|Articles|September 7, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-10-05-2016
  • Volume 11
  • Issue 10

Capsugel Announces Expansion at Quakertown Facility

Capsugel is expanding the facility to meet demand for micronization services for clinical and commercial manufacturing.

On Sept. 7, 2016, Capsugel announced that it will be expanding its Quakertown, PA facility to meet demand for micronization services for clinical and commercial manufacturing. The expansion will double the size of its current pilot-scale capacity for clinical-trial quantities and increase the number of suites for commercial manufacturing.

The Quakertown facility, which Capsugel acquired as part of its purchase of Xcelience and Powdersize in January 2016, operates as a full-service provider of particle-size reduction and particle-size control/classification technologies for pharmaceutical customers. The acquisition expanded the company’s suite of bioavailability tools aimed at improving the bioavailability of APIs with either dissolution or solubility challenges. In addition to enabling increased capacity, the added suites will include single-use containment technologies to accommodate potent and highly potent compounds. The new equipment and suites are scheduled to be operational by January 2017.

Source: Capsugel


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.